Bombesin antagonist-based radiotherapy of prostate cancer combined with WST-11 vascular targeted photodynamic therapy Journal Article


Authors: Kim, K.; Zhang, H.; La Rosa, S.; Jebiwott, S.; Desai, P.; Kimm, S.; Scherz, A.; O'Donoghue, J. A.; Weber, W. A.; Coleman, J. A.
Article Title: Bombesin antagonist-based radiotherapy of prostate cancer combined with WST-11 vascular targeted photodynamic therapy
Abstract: Purpose: DOTA-AR, a bombesin-antagonist peptide, has potential clinical application for targeted imaging and therapy in gastrin-releasing peptide receptor (GRPr)-positive malignancies when conjugated with a radioisotope such as Y-90. This therapeutic potential is limited by the fast washout of the conjugates from the target tumors. WST-11 (Weizmann STeba-11 drug; a negatively charged water-soluble palladium-bacteriochlorophyll derivative, Tookad Soluble) vascular targeted photodynamic therapy (VTP) is a local ablation approach recently approved for use in early-stage prostate cancer. It generates reactive oxygen/nitrogen species within tumor blood vessels, resulting in their instantaneous destruction followed by rapid tumor necrosis. We hypothesize that the instantaneous arrest of tumor vasculature may provide a means to trap radiopharmaceuticals within the tumor, thereby improving the efficacy of targeted radiotherapy. Experimental Design: GRPr-positive prostate cancer xenografts (PC-3 and VCaP) were treated with Y-90-DOTA-AR with or without VTP. The uptake of radioisotopes was monitored by Cherenkov luminescence imaging (CLI). The therapeutic efficacy of the combined VTP and Y-90-DOTA-AR in PC-3 xenografts was assessed. Results: CLI of Y-90-DOTA-AR demonstrated longer retention of radiotracer within the VTP-treated PC-3 xenografts compared with the non-VTP-treated ones (P < 0.05) at all time points (24-144 hours) after Y-90-DOTA-AR injection. A similar pattern of retention was observed in VCaP xenografts. When Y-90-DOTA-AR administration was combined with VTP, tumor growth delay was significantly longer than for the control or the monotherapy groups. Conclusions: Tumorvascular arrestbyVTPimproves Y-90-DOTA-AR retention in the tumor microenvironment thereby enhancing therapeutic efficacy. (C) 2017 AACR.
Keywords: tumors; generation; ablation; focal therapy; peptide receptors; wst11
Journal Title: Clinical Cancer Research
Volume: 23
Issue: 13
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2017-07-01
Start Page: 3343
End Page: 3351
Language: English
ACCESSION: WOS:000404723400018
DOI: 10.1158/1078-0432.ccr-16-2745
PROVIDER: wos
PMCID: PMC5496795
PUBMED: 28108545
Notes: Article -- Source: Wos
Altmetric Score
MSK Authors
  1. Jonathan Coleman
    184 Coleman
  2. Hanwen Zhang
    29 Zhang
  3. Wolfgang Andreas Weber
    147 Weber
  4. Pooja Desai
    10 Desai
  5. Kwanghee   Kim
    10 Kim